20
Participants
Start Date
November 13, 2020
Primary Completion Date
July 1, 2025
Study Completion Date
June 30, 2026
Treprostinil
Treprostinil (Remodulin) will be administered IV by a standard 3 + 3 dose-escalation approach. This dosing model will be followed until a target dose of 15 mg/kg/min is achieved or if it is medically determined that side effects prevent dose escalation. IV infusion will commence approximately 2-3 hours before transplantation of the kidney graft and will continue for approximately 48 hours after completion of surgery, unless hemodynamic changes or tolerability require discontinuation of treprostinil.
RECRUITING
Rhode Island Hospital, Providence
Collaborators (1)
University of Rhode Island
OTHER
United Therapeutics
INDUSTRY
Rhode Island Hospital
OTHER